Excalipoint Therapeutics Announces Clinical Trial Collaboration with Roche to Evaluate EXP011 in DLL3‑Expressing Solid Tumors July 7, 2026
Novartis to acquire Myricx Bio for ADCs with N-myristoyltransferase inhibitor (NMTi) payloads July 7, 2026
Positive Ph 3 Results for Epcoritamab + Lenalidomide in R/R DLBCL Patients Demonstrated Statistically Significant PFS Improvement July 7, 2026
Pyxis Oncology Announces Up to $114M Private Placement Financing to Advance MICVO Through Key Clinical Milestones July 7, 2026
Astex Announces Exclusive Research Collaboration and License Agreement with Genentech for Breast Cancer Therapy Program July 7, 2026
Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Ph 3 Registrational Trial of APG-157 in Head and Neck Cancer July 7, 2026
Ph 3 AURORA Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced NSCLC Patients with Inadequate Response to Immune Checkpoint Inhibitors initiated July 7, 2026
Positive Interim Ph 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability of PAS-004, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion Announced July 7, 2026
Results From the eNRGy Trial of Zenocutuzumab in Patients with NRG1+ Cholangiocarcinoma published in Journal of Clinical Oncology (JCO) July 7, 2026
Ph 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease July 7, 2026
Positive Ph 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control, Reported July 7, 2026
Divarasib shows superiority in head-to-head Ph 3 trial against sotorasib or adagrasib in NSCLC July 7, 2026
ESMO GI 2026: Ph 1/2 Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer Presented July 7, 2026
HETRONIFLY (serplulimab) recommended by the NICE for routine use within the NHS in England and Wales July 7, 2026
TEPKINLY (epcoritamab) in Combination with Lenalidomide & Rituximab Approved by the European Commission for the Treatment of R/R Follicular Lymphoma July 7, 2026
